Fulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

bluebird bio to Present Data from Clinical Development Program of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

Editas Medicine to Participate in Upcoming Investor Conferences

Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

CytomX Therapeutics to Present at Upcoming Healthcare Conferences

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

Blueprint Medicines to Present at Upcoming Investor Conferences in September

Voyager Therapeutics To Present At Upcoming Investor Conferences In September 2019

MyoKardia to Participate in September Investor Conferences

MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

bluebird bio Announces Investor Events in September

Constellation Pharmaceuticals to Participate in Two Investor Conferences

MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)

Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease

Voyager Therapeutics Reports Second Quarter 2019 Financial Results And Corporate Highlights

Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From Stride 3 Trial

Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Zafgen Reports Second Quarter 2019 Operating and Financial Results

MyoKardia to Present at 2019 Wedbush PacGrow Healthcare Conference

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

NinePoint Medical Announces FDA Clearance for Pancreatic and Biliary Applications of the NvisionVLE® Imaging System

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

NinePoint Medical Announces FDA Clearance for Pancreatic and Biliary Applications of the NvisionVLE® Imaging System

MyoKardia Reports Second Quarter 2019 Financial Results

Jounce Therapeutics Reports Second Quarter 2019 Financial Results

GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results

CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Updatec

Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference

CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conferencec

Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer

Editas Medicine Announces Second Quarter 2019 Results and Update

GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference